Experimental study of the acute toxicity and analgesic activity of 1-aryl-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline derivatives

Targeted chemical modification of a naturally occurring isoquinoline alkaloid yielded two hitherto undescribed derivatives – 1-(2-bromo-4,5-methylenedioxyphenyl)-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline hydrochloride and 1-(3,4-dimethoxyphenyl)-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline hydrochloride – whose acute toxicity and analgesic activity were evaluated experimentally in white laboratory mice. Acute toxicity was established via stepwise ascending oral dosing, and the median lethal dose (LD50) was determined by the Litchfield–Wilcoxon method: 1107.9 mg/kg (1017.3–1217.5) for the first compound and 299.1 mg/kg (245.7–341.6) for the second, revealing the latter to be approximately 3.7-fold more toxic. Analgesic activity was benchmarked against the reference NSAID ketoprofen across three validated nociceptive models – thermal (hot plate), acetic acid-induced writhing, and acetylcholine-induced writhing. In the thermal pain paradigm, both derivatives elicited statistically robust analgesia, with the dimethoxy-substituted compound attaining superior efficacy (63.0%) at a comparatively modest dose (1.0 mg/kg). Both compounds likewise demonstrated significant peripheral antinociception in the acetic acid-induced writhing assay across the entire dose range examined (peak efficacies of 63.2% and 66.7%, respectively). In the acetylcholine-induced writhing model, however, ketoprofen retained significant efficacy at every dose tested, whereas the novel compounds proved largely inactive – only the brominated derivative approached significance at 1.0 mg/kg – suggesting that their antinociceptive action is mediated predominantly through central and prostaglandin-dependent peripheral pathways rather than cholinergic mechanisms. Toxicological categorization placed both compounds in hazard class III (moderately hazardous), while the Stefanov classification distinguished them further, assigning the brominated derivative to class IV (low toxicity) and the dimethoxy derivative to class III (moderate toxicity). Collectively, these findings position the 1-aryl-6,7-dimethoxy(methylenedioxy)-1,2,3,4-tetrahydroisoquinoline scaffold as a compelling molecular platform for the rational design of low-toxicity, highly selective analgesic agents.

Hali tarjima qilinmagan